Horien Biotech (stock code: 7814), a leading domestic manufacturer of high-end collagen medical devices, officially listed on the OTC market today (July 16th), successfully transitioning from the Emerging Stock Market to the OTC market! Leveraging its strong R&D capabilities and deep technological barriers, Horien Biotech has recently delivered outstanding performance in revenue, international certifications, global market expansion, and the establishment of a top-tier biomedical raw material supply chain. This demonstrates the powerful momentum of its dual-engine strategy of "deepening existing medical device development and developing high-end innovative medical devices," attracting significant attention from the capital market.

 Driven by continued strong demand in the US, Taiwan, and overseas markets, Horien Biotech achieved a remarkable 209.29% revenue growth in June, marking a significant milestone for its OTC listing. In addition to its strong fundamentals, the company has also made breakthrough progress in its overseas expansion.

 On July 7th, Horien Biotech successfully obtained three high-risk (highest level Class 4) medical device market licenses in Thailand, successfully entering the ASEAN high-end medical device market. Furthermore, the Philippines and Vietnam are expected to obtain Class III medical device certifications soon, signifying that the company's strategic layout in the Southeast Asian market is nearing completion. Moreover, the company's highly anticipated bio-ink innovative product is planned for export to the European market by the end of this year, extending its international footprint from Asia to Europe and America, and is expected to see a surge in global revenue contributions.

 In the research and development of high-end innovative medical devices, Horien Biotech has achieved a disruptive world-class breakthrough. The company's independently developed "biodegradable ureteral stent" has successfully obtained a Taiwanese invention patent and is expected to soon obtain invention patents in the United States, Europe, and China.

 Currently, this innovative product has successfully completed sample development and has been officially delivered for animal testing. Since no other company in the industry has obtained relevant medical device certifications at this stage, Horien Biotech is at the forefront globally. This product not only solves the clinical pain point of traditional stents requiring secondary surgery for removal but also targets a pristine blue ocean market worth billions of US dollars with no competition. Meanwhile, collagen regeneration patches developed using the core "advanced decellularization technology," primarily targeting surgical and orthopedic tissue repair, have recently entered the trial production stage, providing a strong profit foundation for the medium- to long-term product line.

 To meet the explosive global demand and ensure a secure supply of high-end medical device raw materials, Horien Biotech's subsidiary, Shengli Biotechnology Co., Ltd., has officially signed a Memorandum of Understanding (MOU) and cooperation agreement with Taiwan Sugar Corporation and Taiwan Livestock Products Import & Export Corporation, conforming to ISO 13485 (Medical Device Quality Management System) and ISO 22442 (Risk Management of Medical Devices Using Animal Tissue).

 This move not only establishes a medical-grade animal-derived raw material supply chain with internationally high standards but also fundamentally breaks the long-standing monopoly of international biomedical giants, leading Taiwan's traditional livestock industry towards a high-value-added biomedical field.

 Horien Biotech Chairman Tsai Kuo-Tien stated that the successful listing on the over-the-counter market is a significant milestone in Horien Biotech's development history. Looking ahead, the company will continue to deepen its global market penetration by leveraging top-tier medical-grade raw materials and groundbreaking high-end medical devices and drugs, building upon its existing dental and surgical channels. With international certifications secured and innovative product lines entering their harvest period, Horien Biotech will achieve steady and rapid growth, creating maximum value for all shareholders and the Taiwanese biotech industry.

Report Link: